Jeffrey J Swigris1, David A Andrae2, Tara Churney3, Nathan Johnson2, Mary Beth Scholand4, Eric S White5, Alison Matsui6, Karina Raimundo6, Christopher J Evans2. 1. Interstitial Lung Disease Program, National Jewish Health, Denver, Colorado. 2. Endpoint Outcomes, Boston, Massachusetts. 3. Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, Colorado. 4. Division of Pulmonary Medicine, University of Utah, Salt Lake City, Utah. 5. Interstitial Lung Disease Program, University of Michigan, Ann Arbor, Michigan; and. 6. Genentech, South San Francisco, California.
Abstract
Rationale: Several new drugs for idiopathic pulmonary fibrosis (IPF) are in development. Tools are needed to assess whether these drugs benefit patients on outcomes that matter most to them. Health-related quality of life (HRQL) is one such outcome. It is influenced by many factors, but symptoms and their impacts are two strong drivers. Objectives: To develop a questionnaire to assess symptoms, disease impacts, and HRQL specifically for patients with IPF. Methods: Working with the U.S. Food and Drug Administration through the Drug Development Tool Qualification process, focus groups, concept elicitation, and cognitive debriefing interviews were conducted to inform the development of a 44-item pilot questionnaire. The pilot paper-and-pen questionnaire was migrated to an equivalent electronic version and field-tested in a 14-day study. Response data were subjected to psychometric testing, including exploratory factor analysis, item calibration using item response theory models, test-retest reliability, and validity testing.Measurements and Main Results: A total of 125 patients with IPF (62.4% men) completed the longitudinal study. The mean ± SD age of the cohort was 69 ± 7.60 years, and the mean FVC% predicted was 71 ± 20.0. After factor and item analyses, 35 items were retained, and these comprise the two modules (symptoms and impacts) of the Living with IPF (L-IPF) questionnaire. The L-IPF yields five scales demonstrating good psychometric properties, including correlation with concurrently collected FVC% predicted and the ability to discriminate between patients with differing levels of IPF severity.Conclusions: The L-IPF is a new questionnaire that assesses symptoms, disease impacts, and HRQL in patients with IPF.
Rationale: Several new drugs for idiopathic pulmonary fibrosis (IPF) are in development. Tools are needed to assess whether these drugs benefit patients on outcomes that matter most to them. Health-related quality of life (HRQL) is one such outcome. It is influenced by many factors, but symptoms and their impacts are two strong drivers. Objectives: To develop a questionnaire to assess symptoms, disease impacts, and HRQL specifically for patients with IPF. Methods: Working with the U.S. Food and Drug Administration through the Drug Development Tool Qualification process, focus groups, concept elicitation, and cognitive debriefing interviews were conducted to inform the development of a 44-item pilot questionnaire. The pilot paper-and-pen questionnaire was migrated to an equivalent electronic version and field-tested in a 14-day study. Response data were subjected to psychometric testing, including exploratory factor analysis, item calibration using item response theory models, test-retest reliability, and validity testing.Measurements and Main Results: A total of 125 patients with IPF (62.4% men) completed the longitudinal study. The mean ± SD age of the cohort was 69 ± 7.60 years, and the mean FVC% predicted was 71 ± 20.0. After factor and item analyses, 35 items were retained, and these comprise the two modules (symptoms and impacts) of the Living with IPF (L-IPF) questionnaire. The L-IPF yields five scales demonstrating good psychometric properties, including correlation with concurrently collected FVC% predicted and the ability to discriminate between patients with differing levels of IPF severity.Conclusions: The L-IPF is a new questionnaire that assesses symptoms, disease impacts, and HRQL in patients with IPF.
Authors: Lechosław Paweł Chmielik; Grażyna Mielnik-Niedzielska; Anna Kasprzyk; Tomasz Stankiewicz; Artur Niedzielski Journal: Med Sci Monit Date: 2022-06-09
Authors: Marlies Wijsenbeek; Maria Molina-Molina; Olivier Chassany; John Fox; Liam Galvin; Klaus Geissler; Katherine M Hammitt; Michael Kreuter; Teng Moua; Emily C O'Brien; Ashley F Slagle; Anna Krasnow; Matthew Reaney; Michael Baldwin; Natalia Male; Klaus B Rohr; Jeff Swigris; Katerina Antoniou Journal: ERJ Open Res Date: 2022-05-03
Authors: Anna J Podolanczuk; Alyson W Wong; Shigeki Saito; Joseph A Lasky; Christopher J Ryerson; Oliver Eickelberg Journal: Am J Respir Crit Care Med Date: 2021-06-01 Impact factor: 21.405
Authors: Surinder S Birring; Donald M Bushnell; Michael Baldwin; Heiko Mueller; Natalia Male; Klaus B Rohr; Yoshikazu Inoue Journal: Eur Respir J Date: 2022-06-02 Impact factor: 33.795
Authors: Detlef Kirsten; Ulrike de Vries; Ulrich Costabel; Dirk Koschel; Francesco Bonella; Andreas Günther; Jürgen Behr; Martin Claussen; Stefan Schwarz; Antje Prasse; Michael Kreuter Journal: Pneumologie Date: 2021-09-14